 Founded on 28th March 1995, Simcere has swiftly evolved from a pure pharmaceutical distributor into a leading pharmaceutical manufacturer and supplier in China's rapidly growing pharmaceutical market. Simcere currently operates one research and development center, two nationwide sale and marketing subsidiaries and four GMP manufacturing facilities. It has approximately 4,300 employees in China.
Innovation is the key driver of our growth towards excellence. In recent years, we have refined our strategy to focus on innovative pharmaceuticals and first-to-market generics.
Simcere's sales and marketing network has established a deep market penetration and broad coverage across China. Our current portfolio is comprised of innovative pharmaceuticals, first-to-market generics and branded generics in five core disease areas ¨C oncology, neurology, cardiovascular/cerebrovascular, inflammation and infectious diseases, reflected in 50+ product combinations.Innovation is the key driver of our growth towards excellence. In recent years, we have refined our strategy to focus on innovative pharmaceuticals and first-to-market generics.
Endu®, the first and only recombinant human endostatin in the world as a proprietary anti- angiogenesis drug, is approved as a first line therapy for Non-Small Cell Lung Cancer in China. It was the gold medal winner of the '10th Outstanding Chinese Patent Invention Award' and the second prize winner of the '2008 National Tech & Invention Award.'
Bicun®, the first to market Edaravone Injection on China market, was the first synthetic free radical scavenger providing treatment for stroke.
Iremod®, a novel Disease Modifying Anti-rheumatic Drug ("DMARD") developed by our in-house team and the first Iguratimod ever launched, it represents a new option for the treatment of rheumatoid arthritis.
Other 100Mn RMB brands include:
Anxin®, China's first to market Biapenem Injection used for the treatment of severe infections.
Sinofuan®, the world's first anti-cancer sustained-release fluorouracil implant.
Jiebaisu®, China's first to market Nedaplatin Injection.
Yingtaiqing®, China's first to market Diclofenac Sodium Sustained Release Capsule.
Zailin®, China's first to market pediatric Amoxicillin, won the China well known brand.
Biqi®, Smectite powder for diarrhea, passed the EU-GMP inspection and received international GMP-certification from the Finnish Medicines Agency in 2011.
For sustainable growth, Simcere established the Simcere Pharmaceutical R&D Institute in 2003. Simcere has invested 6-11% of the company's annual revenue into R&D in recent years, reflecting our strong commitment to innovation. We also actively collaborate with domestic and international companies and research institutes to develop innovative drugs including biologics. We have successful formed partnerships with international companies including BMS, OSI (now Astellas), Epitomics (now Appexigen), GSK and Merck. Currently, we have multiple projects in innovative pipeline and generic pipeline respectively. Since 2010, we have obtained IND approvals for 7 innovative drugs from the CFDA.
Simcere was the first Chinese chemical and biological drug company to list on the New York Stock Exchange with IPO proceeds reaching US$ 261 million in 2007. In 2013, the company went private for strategic consideration.
Simcere will continue on its path as a leading Chinese pharmaceutical company. We are working tirelessly to provide more effective medicines for our patients and to earn the respect from our clients and the society. |
News